DDInter172 DDInter1825
Belatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each. It is produced through recombinant DNA technology in mammalian CHO cells. The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. It is approved for the treatment of rheumatoid arthritis. Belatacept selectively blocks the process of T-cell activation. It was developed by Bristol-Myers-Squibb. Belatacept is only 2 amino acids different
Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate. Besides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and is currently under investigation for the treatment of psoriasis. Known adverse effects include nausea and headache as well as more serious immunologic and hematological adverse effects. Tofacitinib is marketed under the brand name Xeljanz by Pfizer.
Tofacitinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Tofacitinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Tofacitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Esomeprazole
Tofacitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Tofacitinib {u} may lead to a major life threatening interaction when taken with {v} Brexucabtagene autoleucel
Tofacitinib {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Tofacitinib may cause a minor interaction that can limit clinical effects when taken with Modafinil
Tofacitinib may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole
Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Tofacitinib may lead to a major life threatening interaction when taken with Brexucabtagene autoleucel
Tofacitinib may lead to a major life threatening interaction when taken with Fingolimod